The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022.
The proton cohort is divided into two groups: Pragmatic and Randomized. The Pragmatic group enrollment goal of 900 patients was reached on September 1, 2021. The Randomized group enrollment goal of 600 patients was achieved on Friday May 27, 2022. The COMPPARE Team sends a special thanks to the Barbara Ann Karmanos Cancer Institute, Detroit, MI, which enrolled the 600th Randomized proton patient.
The team now seeks to complete its enrollment goal of 1,500 men treated with photons between the ages of 30-85 across the US. Participants will answer brief surveys regarding treatment choice, quality of life, and side effects. As of May 27, this photon cohort had accrued 800 patients.
To check study accrual progress, view enrollment updates here.
